GlassScriptPhysician profile
Terri L Tomlin
NPI 1447207196
$988.25
in general payments reported to CMS, 2019-2025
11 companies · $134 in 2025
The $134 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.92 · 2020: $76.86 · 2021: $95.30 · 2022: $16.01 · 2023: $251 · 2024: $402 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $258.64 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $237.63 | 2023-2024 | Jornay Pm |
| Corium, LLC | $149.83 | 2023-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $66.38 | 2020-2024 | Varivax, Gardasil, Vaxelis |
| Tris Pharma INC | $62.61 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Pfizer INC. | $61.29 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.96 | 2020-2021 | |
| Neos Therapeutics, LP | $31.37 | 2020 | |
| Sanofi-Aventis U.S. LLC | $26.55 | 2023 | |
| Sobi, INC | $22.57 | 2024 | |
| Collegium Pharmaceutical, INC. | $17.42 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Tomlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.